Literature DB >> 1830630

The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study.

M A Smith1, J G Smith.   

Abstract

This study examines the occurrence, subtype and possible significance of haemopoietic inhibitory T cells (HIT cells) in patients with myelodysplasia (n = 21), acute myeloblastic leukaemia (n = 8) and in normal subjects (n = 13) using an autostimulary CFU-GM stem cell assay. HIT cells were detected when colony numbers increased by 30% or more following T-lymphocyte subpopulation ablation. HIT cells occurred in 28% of the MDS patients, were always CD8-positive and never occurred in the normal subjects. Sequential studies in MDS patients with HIT cells and treated with low dose Ara-C showed no correlation between occurrence of these cells and clinical outcome. HIT cells appear to be a clinically irrelevant manifestation of the cell dysfunction associated with MDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830630     DOI: 10.1016/0145-2126(91)90028-r

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

Review 1.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Treatment of myelodysplastic syndrome with cyclosporin A.

Authors:  Shuchang Chen; Bin Jiang; Wanming Da; Ming Gong; Mei Guan
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

3.  Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood.

Authors:  Ayami Yoshimi; Marry M van den Heuvel-Eibrink; Irith Baumann; Stephan Schwarz; Ingrid Simonitsch-Klupp; Pascale de Paepe; Vit Campr; Gitte Birk Kerndrup; Maureen O'Sullivan; Rita Devito; Roos Leguit; Miguel Hernandez; Michael Dworzak; Barbara de Moerloose; Jan Stary; Henrik Hasle; Owen P Smith; Marco Zecca; Albert Catala; Markus Schmugge; Franco Locatelli; Monika Führer; Alexandra Fischer; Anne Guderle; Peter Nöllke; Brigitte Strahm; Charlotte M Niemeyer
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

4.  Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.

Authors:  Paulo V Campregher; Santosh K Srivastava; H Joachim Deeg; Harlan S Robins; Edus H Warren
Journal:  Exp Hematol       Date:  2009-12-24       Impact factor: 3.084

5.  Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.

Authors:  Hussein A Abbas; Patrick K Reville; Xianli Jiang; Hui Yang; Alexandre Reuben; Jin Seon Im; Latasha Little; Jefferson C Sinson; Ken Chen; Andrew Futreal; Guillermo Garcia-Manero
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

Review 6.  Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.

Authors:  David A Sallman; Thomas Cluzeau; Ashley A Basiorka; Alan List
Journal:  Front Oncol       Date:  2016-06-16       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.